Cargando…

Molecular screening for an underlying myeloproliferative neoplasm in patients with stroke: who and how?

Detalles Bibliográficos
Autor principal:	Langabeer, Stephen E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106119/ https://www.ncbi.nlm.nih.gov/pubmed/32269979 http://dx.doi.org/10.5045/br.2020.55.1.67

Ejemplares similares

Molecular screening for an underlying myeloproliferative neoplasm in rheumatology patients
por: Langabeer, Stephen
Publicado: (2022)

Hypercalcemia as a biomarker of myeloproliferative neoplasms?
por: Langabeer, Stephen E.
Publicado: (2019)

Dual Drivers in the Myeloproliferative Neoplasms: An Underestimation?
por: Langabeer, Stephen E.
Publicado: (2023)

CALR mutations in myeloproliferative neoplasms: An unfolding story
por: Langabeer, Stephen E.
Publicado: (2020)

Concurrent chronic myeloid leukemia and CALR-mutated myeloproliferative neoplasm
por: Langabeer, Stephen E.
Publicado: (2020)

MPL exon 10 mutations in Irish patients with a suspected myeloproliferative neoplasm
por: Lee Tokar, Lisa, et al.
Publicado: (2021)

CALR mutation analysis is not indicated in patients with splanchnic vein thrombosis without evidence of a myeloproliferative neoplasm: a micro-review
por: Langabeer, Stephen E.
Publicado: (2016)

Screening for an underlying myeloproliferative neoplasm in patients with thrombocytosis post-induction chemotherapy for acute myeloid leukemia
por: Langabeer, Stephen E.
Publicado: (2020)

Molecular Diagnostics with Laboratory Finding in Patients with Myeloproliferative Neoplasms
por: MAKANI, Zahra, et al.
Publicado: (2017)

Reduction in molecular diagnostics of myeloproliferative neoplasms during the COVID-19 pandemic
por: Langabeer, Stephen E.
Publicado: (2020)

Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience
por: Begna, K, et al.
Publicado: (2016)

Effects of Mutational Combinations on Philadelphia-Negative Myeloproliferative Neoplasms
por: Ipek, Yonal-Hindilerden, et al.
Publicado: (2017)

Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
por: Li, Bing, et al.
Publicado: (2017)

Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches
por: Haslam, Karl, et al.
Publicado: (2016)

Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms
por: Machado-Neto, João Agostinho, et al.
Publicado: (2015)

Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms
por: Brecqueville, M, et al.
Publicado: (2011)

Nontraumatic acute subdural hematoma associated with the myelodysplastic/myeloproliferative neoplasms
por: Ichimura, Shinya, et al.
Publicado: (2012)

The JAK2 gene as a protagonist in chronic myeloproliferative neoplasms
por: de Freitas, Renata Mendes, et al.
Publicado: (2013)

Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes
por: Brecqueville, M, et al.
Publicado: (2011)

SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms
por: Borsani, Oscar, et al.
Publicado: (2023)

Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice
por: Minakawa, Keiji, et al.
Publicado: (2021)

SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms
por: Oddsson, A, et al.
Publicado: (2014)

Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6–LYN gene fusion
por: Telford, N, et al.
Publicado: (2016)

Rare gene fusion rearrangement SPTNB1-PDGFRB in an atypical myeloproliferative neoplasm
por: Furtado, Vanessa Fiorini, et al.
Publicado: (2018)

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients
por: Cassinat, Bruno, et al.
Publicado: (2020)

Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 World Health Organization diagnostic criteria
por: Song, Ik-Chan, et al.
Publicado: (2019)

Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms
por: Schneider, Rebekka K, et al.
Publicado: (2014)

p27(KIP1) and PTEN cooperate in myeloproliferative neoplasm tumor suppression in mice
por: Shao, Jingchen, et al.
Publicado: (2016)

JAK2 exon 12 mutation-positive myeloproliferative neoplasm associated with recurrent thromboembolism
por: Tavakoli, Vahid, et al.
Publicado: (2017)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

Molecular pathogenesis of the myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2021)

Ph-Negative Chronic Myeloproliferative Neoplasm (Primary Myelofibrosis) – as One of the Reasons of the Budd-Chiari Syndrome
por: Sokolova, M., et al.
Publicado: (2012)

Screening for Latent Polycythemia Vera in Renal Cell Carcinoma–Associated Erythrocytosis
por: Langabeer, Stephen E.
Publicado: (2023)

JAK2V617F mRNA metabolism in myeloproliferative neoplasm cell lines
por: Nauroy, P, et al.
Publicado: (2014)

Myelodysplasia-Related Features of Acute Myeloid Leukemia Evolving From Philadelphia-Negative Myeloproliferative Neoplasms
por: Kim, Jae-Ryuk, et al.
Publicado: (2016)

IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis
por: Cumbo, Cosimo, et al.
Publicado: (2021)

The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm
por: O’Hagan Henderson, Samantha, et al.
Publicado: (2021)

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm
por: Gangat, Naseema, et al.
Publicado: (2022)

Mutational Analysis of SH2B3 in Korean Patients With BCR-ABL1 Negative Myeloproliferative Neoplasm
por: Kim, Namhee, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pdmfkb6mpd4nvv5qqdo0q6u84n